The overall goal of this project is to characterize the nature and extent of abnormalities in phospholipid (PL) metabolism that are associated with neuronal dysfunction and degeneration in Alzheimer's disease (AD). It is hypothesized that abnormalities in the metabolism of phosphatidylcholine (PC) and possibly other PLs are associated specifically with neuronal dysfunction and degeneration in AD and are distinct from findings in other neurodegenerative diseases or changes that may occur during normal aging. In order to test this hypothesis, we will measure levels of PLs and water-soluble precursors and metabolites of PC and other PLs in brain tissue obtained at autopsy from patients with AD, Huntington's disease, and from two groups of control subjects: one with ages between 20 and 40, and the second with ages between 60 and 80 years old. Brain samples will be from frontal, temporal, and occipital cortex; hippocampus; and the caudate nucleus and ventral forebrain CH 1-4 nuclear region. The proposed research takes advantage of resources in the Massachusetts ADRC, including the Tissue Resource Center of the Neuropathology Core and biostatistical expertise in the Administrative Core. Identification of characteristic abnormalities in the PL metabolism in brains of patients with AD may provide new explanations for neuronal dysfunction and death.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-10
Application #
3768051
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Dujardin, Simon; Bégard, Séverine; Caillierez, Raphaëlle et al. (2018) Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol Commun 6:132
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
DeVos, Sarah L; Corjuc, Bianca T; Commins, Caitlin et al. (2018) Tau reduction in the presence of amyloid-? prevents tau pathology and neuronal death in vivo. Brain 141:2194-2212
Lee, Christopher M; Jacobs, Heidi I L; Marquié, Marta et al. (2018) 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. J Alzheimers Dis 62:1691-1702
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Emerson, Sarah C; Waikar, Sushrut S; Fuentes, Claudio et al. (2018) Biomarker validation with an imperfect reference: Issues and bounds. Stat Methods Med Res 27:2933-2945
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739

Showing the most recent 10 out of 966 publications